Can a digestive enzyme help premature babies tolerate milk?

NCT ID NCT07784062

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Sep 01, 2026 · Updated 3 times

Summary

This trial tests whether adding lactase enzyme to milk feeds helps preterm infants digest lactose and reduce feeding intolerance—a common problem in babies born before 34 weeks. Eligible infants are randomly assigned to receive either lactase-treated feeds or a placebo, and researchers compare signs like stomach residual volume, abdominal distension, vomiting, and diarrhea. The goal is to see if lactase supplementation supports better feeding progression and growth in these vulnerable newborns.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Lactase enzyme added to milk feeds
What this could lead to
If effective, lactase-treated feeds could become a simple, low-cost way to help preterm infants tolerate feeding better, potentially reducing hospital stays and improving growth.
What could go wrong
This is a small, early-stage trial, so results may not apply broadly. Lactase may not significantly improve symptoms, and there is always a risk of unexpected side effects in fragile preterm infants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

70 people

The number who actually took part.

Started

Nov 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

0 to 28 days

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria * Gestational age \<34 weeks. * ≥2 symptoms suggestive of lactose intolerance: abdominal distension, abdominal pain, diarrhea, or diaper/nappy dermatitis. * Feeding intolerance defined by GRV \>3 mL/kg or the specified vomiting/stool/abdominal-distension. Exclusion Criteria: * Severe congenital malformations, including GI or cardiac defects. * NEC according to Bell's staging criteria. * Congenital diarrhea. * Hemodynamic instability requiring inotropes. * Amino-acid-based or lactose-free formula. * Guardian declines consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Feeding intolerance in preterm infants are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • NICU of Ain shams university hospitals

    Cairo, Cairo Governorate, 02, Egypt